Moderna to Present Broad Infectious Disease Research at ESCMID 2025

Moderna, Inc. is set to showcase a broad range of infectious disease research at the upcoming European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria. The event, scheduled to take place from April 11 to 15, 2025, will focus on various infectious diseases, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox.

The company is gearing up to present twelve scientific research projects at ESCMID 2025, incorporating three oral presentations, one e-poster presentation, and eight poster presentations. These presentations will shed light on Moderna’s extensive research endeavors in the realm of respiratory and emerging infectious diseases.

In the domain of COVID-19, Moderna will present significant research findings. For instance, the company will delve into the immunogenicity of mRNA COVID-19 vaccines encoding JN.1 and KP.2 against SARS-CoV-2 sublineages in adult participants. This research will be showcased in an oral presentation by Frances Priddy on April 12 at 11:00 in Hall 9. Moderna will also explore the relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine as compared to mRNA-1273. This subgroup analysis will be presented orally by Spyros Chalkias on April 13 at 11:00 in Hall 9.

Moreover, Moderna plans to present its clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine in a poster presentation by Spyros Chalkias on April 12 at 12:00 in the Poster Hall. The company will also highlight the immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged 12 years and above in another poster presentation by Christina Grassi on the same day at the same location.

In the realm of RSV, Moderna will share insights on the six-month immunogenicity of the mRNA-1345 RSV vaccine in adults aged 60 years and above in an e-poster presentation by Mihir Desai on April 12 at 08:30 in Arena 1. Additionally, the company will delve into the safety and immunogenicity of mRNA-1345 revaccination at 24 months in adults aged 60 years and above, with a poster presentation by Mihir Desai on April 15 at 12:00 in the Poster Hall.

The presentations at the ESCMID 2025 Global Congress highlight Moderna’s commitment to advancing research in the field of infectious diseases, showcasing its dedication to improving global health outcomes through innovative vaccine development.